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ABSTRACT  
Objective: The objective of the study was to evaluate the dose dependent effects of atorvastatin on rat kidneys.  
Methods: The selected doses of atorvastatin were administered orally for 17 days to rats. The statin induced nephrotoxicity was accessed by 
carrying out renal function tests and is by renal histopathology analysis. Measurements of antioxidant enzymes were also carried out to check 
whether atorvastatin at the selected dose level interfere with any of the antioxidant system. Atorvastatin at three doses 5mg/kg, 10mg/kg and 
20mg/kg was tested. 
Results: Higher doses of atorvastatin exhibits considerable degree of renal toxicity in rats, while the low doses do not interfere with renal functions 
in rats. Atorvastatin at all the tested dose levels not interfere with cellular anti-oxidant mechanisms.  
Conclusions: Atorvastatin at 20mg/kg exhibit significant toxicity on rat kidneys. Atorvastatin at the selected dose level does not interfere with any 
of the antioxidant mechanisms. It indicated that atorvastatin not cause oxidative stress induced renal damage and rhabdomyolysis may be the 
reason for renal damage induced by atorvastatin at the high dose level.  
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INTRODUCTION 
Statins are important class of cholesterol lowering drugs which act 
by inhibiting HMG Co reductase, the rate limiting enzyme involved in 
cholesterol biosynthesis pathway. Currently a lot of researches are 
in progress to reveal the pleotropic effects of statins including anti-
inflammatory activity, antioxidant activity, nephro-protective, anti 
proliferative and immunosuppressive properties [1]. A review of 
available registry data suggested that statins besides provide a 
cardio protective effect, improve kidney functions and renal 
dynamics in chronic kidney disease and renal transplant 
patients[2,3,4]. Some literatures were available which indicated the 
protective effect of statins in nephrotoxicity induced by 
gentamycin[5,6] cisplatin[7], cyclosporine[8]etc. It was reported 
that the antioxidant effect of statins are responsible for the clinical 
benefits of statins in renal functions [9,10]. Statins exhibit anti-
oxidant activities by a lot of mechanisms including enhancing the 
redox regulatory activity of thioredoxin[11,12] by reducing 
myeloperoxidase and nitric oxide derived oxidants production[13], 
by decreasing the expression of essential NADPH oxidase,[14,15] by 
increasing the serum paroxanase I activity[16] and by increasing 
serum glutathione level[17]. Now it is considered that small dose of 
statins are safe to prescribe in moderate renal impairment, and 
might even preserve glomerular filtration[18]. Faikah gueler et al 
reported that postischemic acute renal failure is reduced by short-
term cerivastatin treatment [19]. Zorica Nesic et al reported that 
single-dose intravenous simvastatin treatment attenuates renal 
injury in an experimental model of ischemia-reperfusion in Rats 
[20]. Alejandro R. Chade et al reported that simvastatin promotes 
angiogenesis and prevents micro vascular remodeling in chronic 
renal ischemia in a pig model [21]. But there are some literature are 
available which indicated that chronic use of statins in high dose 
may leads to direct renal tubular toxicity[22, 23], characterized by 
acute as well as chronic tubule interstitial nephritis, increase in 
fibrous tissue with tubular atrophy and casts formation and 
detachment of renal tubular cells[24]. 
Our group already published the dose dependent effect of 
atorvastatin against vancomycin induced renal damage in 5th 
volume and 3rd
On 17
 issue, in the year 2013 of the same journal [25]. We 
got the protective effect only at 10mg/kg of atorvastatin and a dose 
of 20mg/kg failed to provide a protective effect. So this work was 
focused to reveal the dose dependent effect of atorvastatin in rat 
kidneys and to reveal the effect of the selected doses of atorvastatin 
on anti-oxidant status of rat. That is, an attempt was made to find 
whether atorvastatin at the high dose may induce an oxidative stress 
capable to induce renal damage in albino rats.  
MATERIALS AND METHODS 
Animals 
Wistar rats of either sex having weight of 150-300g were used for 
the study. Animals were housed in polypropylene cages, bedded 
with paddy husk and provided with standard rodent pellet diet and 
drinking water. The animals were maintained under standard 
conditions of relative humidity, 12 hours light-dark cycle, provided 
with adequate ventilation and ambient room temperature.  
Ethical clearance 
All the experimental protocol was approved by the institutional animal 
ethics committee, Medical College, Thiruvananthapuram. The care of 
animals was taken as per the guidelines of the Committee for the 
Purpose of Control and Supervision of Experiments on 
Animals(CPCSEA); Department of Animal Welfare, Government of India. 
Drug 
Atorvastatin reference sample was supplied as the gift sample by 
Ranbaxy pharmaceuticals, Pvt Ltd, Punjab.  
Animals grouping and treatments 
A total of 24 animals were used for the study. They were further 
divided into four groups of 6 animals in each group  
Group I (6 rats): Received distilled water for 17 days  
Group 2(6 rats): Received atorvastatin 5mg/Kg orally for 17 days. 
Group 3(6 rats): Received atorvastatin 10mg/Kg orally for 17days. 
Group 4 (6 rats): Received atorvastatin 20 mg/Kg orally for 17 days. 
th day of the treatment 24 hr urine was collected from animals in 
all group using metabolic cages and on next day blood samples were 
collected by retro-orbital bleeding under anaesthesia. Both the urine 
and blood samples were subjected to biochemical investigation. 
International Journal of Pharmacy and Pharmaceutical Sciences 
ISSN- 0975-1491               Vol 6, Issue 11, 2014 
Innovare 
Academic Sciences 
Panonnummal et al. 
Int J Pharm Pharm Sci, Vol 6, Issue 11, 401-406 
402 
At the end, all the animals were sacrificed by anaesthetic overdose. 
Kidneys were isolated and washed with normal saline to remove the 
blood and blotted with filter paper. Weights of kidneys were noted 
and right kidney weight was expressed as an organ to body weight 
ratio and was used for antioxidant enzymes measurement. Left 
kidney was subjected to histopathological investigations. 
Biochemical investigations 
Serum and urine analysis 
All the analysis of blood and urine samples were performed in 
advanced clinical research laboratory, Govt Medical College, 
Trivandrum 
1) Blood Urea Nitrogen (vitros BUN/Urea slide method). 
2) Serum and urine creatinine (Vitros CREA slide method) 
3) Urine and serum potassium level (Vitros k+
4) Urine sodium determination (vitros Na
slide method) 
+
Antioxidant enzymes and lipid peroxidation assays 
Preparation of tissue homogenate 
For the antioxidant measurements kidney homogenate prepared in 
140 mM potassium phosphate buffer (pH 7.0) was used. The 
supernatant of homogenate stored at 4
slide method) 
oC and used for the 
antioxidant enzyme assays [25].  
Determination of Homogenate protein (Biuret Method)[25] 
Estimation of protein by Biuret method is based on the formation of 
a blue coloured complex of proteins with cupric icons present in 
biuret reagent and the absorbance of the complex can be measured 
at 540 nm. 
Superoxide dismutase assay (Marklund and 
Marklund1974)[25] 
The assay is based on the principle of conversion ofNitro Blue 
Tetrazolium (NBT) to NBT-diformazan, by superoxides generated by 
xanthine oxidase; which convert xanthine to uric acid and hydrogen 
peroxide. NBT-diformazan absorbs light at 560 nm and that can be 
measured spectrophotometrically. 
Catalase assay (Aebi et al 1984)[25] 
Catalase catalyses the decomposition of hydrogen peroxides to 
water and oxygen and the catalase test is used to detect the presence 
of catalase. The assay is based on the degradation of hydrogen 
peroxide by catalase, in which the decomposition of peroxide is 
followed spectrophotometrically at 240 nm
All the data are presented as mean value ± SEM. Statistical analysis 
was done by using one way ANOVA with post Hoc comparisons 
using Tukey HSD tests. P value less than 0.05 was considered 
significant. 
RESULTS 
In order to study the toxicity potential of atorvastatin on rat kidneys 
three doses of atorvastatin were selected. The measurements of 
various serum and urine biochemical markers for renal toxicity were 
evaluated. The selected doses of atorvastatin were administered 
orally for 17 days, as these doses and duration were already tested 
by our research groups in vancomycin induced nephrotoxicity and 
the results was published [25]. 
The Blood Urea Nitrogen (BUN) is an indicator of renal function; was 
measured for all groups. BUN of control animals was found to be 
40.467±0.715mg/dl. Atorvastatin5mg/kg treated group exhibited a 
BUN value of 41.283±0.825mg/dl which was not significantly 
different from ontrol animals. Atorvastatin treatment at a dose of 
10mg/kg gave a BUN value of 40.069±0.946mg/dl (p=0.988) as 
compared to control treatment. The treatment with atorvastatin 
20mg/kg treatment increased BUN level to 51.783 ±1.015 which 
was significantly higher when compared with control group animals. 
Data shown in figure1.  
Serum creatinine is another important indicator of renal function 
and is increased in impaired kidney function. Serum creatinine 
concentration in control group of animals was 0.467±0.033mg/dl. 
Treatment with atorvastatin5mg/kg and 10mg/kg caused a serum 
creatinine level of 0.417±0307 (p=0.705) and 0.453±0.0453 (p=1) 
respectively as compared to control group which was not 
statistically significant. The treatment with atorvastatin 20mg/kg 
treatment increased serum creatinine to 1.333±0.033significantly 
(p=0.0001) as compared to the control group. Data shown in fig 2. 
Creatinine clearance is considered a direct indicator of renal 
clearance and is reported to be decreased in kidney diseases. In the 
control group animals, the creatinine clearance was 0.4154±0.0309. 
Treatment with atorvastatin5mg/kg and 10mg/kg caused a serum 
creatinine level of 0.4363±0.012 (p=0. 873) and 0.3929±0.0204 
(p=0.846) respectively as compared to control group which were 
not statistically significant. The treatment with atorvastatin 
20mg/kg treatment caused a decrease in creatinine clearance to 
0.0365±0.003; which was statistically significant (p=0.0001) as 
compared to the control group. Data are shown in fig: 3. 
Urine output give an indirect indication of renal function.24 hr 
urine volume was measured at the end of the study in all groups of 
animals. The control group animals on 7
. 
Lipid peroxidation assay (Ohkawa et al 1979)[25] 
Formation of Malondialdehyde (MDA) is the end results of lipid 
peroxidation. The assay is based on the formation of 1:2 adduct of 
MDA with thiobarbituric acid and can be measured 
spectrophotometrically at 532 nm. 
Glutathione content (Modified beutler et al method) [25] 
The assay is based on the interaction of 5-5'dithiobis 2-nitrobenzoic 
acid (DTNB) present in the assay mixture with reduced glutathione 
(GSH) to form the coloured product 2-nitro-5-thiobenzoic acid, 
which can be measured at 412 nm.  
Histopathological studies 
Left Kidney was fixed in 10 % neutral buffered formalin, dehydrated 
with alcohol and xylene, embedded in paraffin wax, sliced to 5 µm 
thick sections using rotary microtome, stained with haematoxylin 
and eosin and subjected to analysis for histological changes using 
microscope. 
Statistical analysis 
th day gave urine output of 
(6.43 ± 0.23) ml. The treatment with atorvastatin 5mg/kg and 
atorvastatin 10mg/kg resulted in a urine output of 6.82±0.28 ml 
(p=0. 637) and 6.27 ±0.23 ml (p=0.954) respectively, the values 
were not significant when compared with control animals. But the 
treatment with atorvastatin 20mg/kg reduces the urine output to 
5.38±0.14 and this reduction in urine volume was significant 
(p=0.018) when compared with control group. Data are shown in 
fig: 4. 
Urine sodium level was found to be 42.1± 1.53mEq/L in the control 
group. The treatment with atorvastatin 5mg/kg, atorvastatin 
10mg/kg and atorvastatin 20mg/kg resulted in a urine sodium level 
of 44.48±1.88 (p=0.910), 40.22 ±1.33 (p=0. 527) and 42.20±1.06 
(p=0. 973) respectively. None of these values were significantly 
different from control group. Urine potassium level of control group 
on 7th
In order to study the effect of selected doses of atorvastatin on 
antioxidant status and to reveal the influence of these factors on 
renal function; measurements of various antioxidant enzymes such 
as superoxide dismutase (SOD), catalase, Glutathione (GSH) and lipid 
per oxidation end products (MDA) were done. The control group 
animals have an SOD activity of 35.828±2.398U/mg protein. The 
treatment with atorvastatin 5mg/kg, atorvastatin 10mg/kg and 
 day of study was observed as 75.15±2.02 mEq/L. The 
treatment with atorvastatin5mg/kg, Atorvastatin 10mg/kg and 
atorvastatin 20mg/kg showed a urine potassium level of 81.25±1.09 
(p=0. 057), 78.2±1.14 (p=0.797) and 79.05±1.24 (p=0. 500) 
respectively. None of these values were significant. Data are shown 
in table: 1. 
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atorvastatin 20mg/kg exhibited an SOD activity of 36.442±1.6118 
(p=0.994), 34.003 ±1.0608 (p=0. 867) and 33.5608±1.1338 (p=0. 
776). None of these values were significant, when compared with 
control group. Data are shown in table 2. The catalase activity of 
water control group was 0.6894±0.0634. The treatment with 
atorvastatin5mg/kg, atorvastatin10mg/kg and atorvastatin 
20mg/kg treated groups had a catalase activity of 0.6147±0.0834 
(p=0. 876), 0.7712± 0.0451 (p=0.844) and 0.6865±0.0827 (p=1) 
respectively. None of these values were statistically significant. Data 
are shown in table 2. The control group showed that MDA level in 
kidney was1.24 ±0.0165. The treatment with atorvastatin 5mg/kg, 
atorvastatin 10mg/kg and atorvastatin 20mg/kg showed an MDA 
level of 1.122±0.0144 (p=0.919), 1.5057 ±0.1687 (p=0.494) and 
1.335±0.1125 (p=0. 954) respectively. None of these values were 
significant. Data are shown in table 2. GSH is an indicator of 
antioxidant function. In control group animals the GSH level was 
0.1574±0.0139. The treatment with atorvastatin 5mg/kg, 
atorvastatin 10mg/kg and atorvastatin 20mg/kg showed a GSH level 
of 0.1611±0.00625 (p=0.992), 0.1301 ±0.0066 (p=0.198) and 
0.1271±0.00865 (p=0. 080) respectively when compared with 
control group. None of these values were significant. Data are shown 
in table 2 
Initial weights of all the animals were taken and on the last day 
change in weight of animals were noted and was expressed in 
percentage. The percentage change in weight of control animals was 
(3.713 ±.445). Treatment with atorvastatin (5mg/kg) resulted in a 
body weight changes of 2.614±0.967 (p=0.664) group and 
atorvastatin 10mg/kg caused a change in body weight to 
3.180±0.7816, (p=0.994), as compared to control groups. The 
treatment with atorvastatin 20mg/kg caused a body weight changes 
of 3.4259±0.286, (p=0.943) as compared to control group. None of 
these changes are statistically significant.  
The kidney was weighed after the various treatment periods and 
was expressed as organ to body weight (%) ratio. The kidney weight 
in control group was 0.314 ±0.009. In groups treated with 
atorvastatin (5mg/kg) the organ to body weight ratio of kidney was 
found to be 0.335±0.011(P=0.710) which was not significantly 
different from control groups. Treatment with atorvastatin 10mg/kg 
causes a organ to body weight ratio of 0.351 ± 
0.019(P=0.263);Which was also not significantly different from 
control groups. The treatment with atorvastatin 20mg/kg resulted 
in significant elevation of this ratio of 0.428±0.012 (P=0.001) as 
compared to control group. Data are shown in fig 5. 
Histopathological examination of the kidney was done after various 
treatments. Atorvastatin at doses 5mg/kg (Fig: 7) and 10mg/kg (Fig: 
8) does not show any characteristic pathological changes compared 
to the control rats. They showed intact tubules and glomeruli as seen 
in normal rats except that a mild glomerular congestion was 
observed with 10mg/kg. Atorvastatin 20mg/kg received rats show 
characteristic pathological changes such as glomerular atrophy, 




Fig. 1: BUN of albino rats given various treatments [(values are 
mean ± SEM). *p=0.001 as compared to control group 
 
Fig. 2: Serum creatinine levels of albino rats given various 




Fig. 3: Creatinine clearance of albino rats given various 




Fig. 4: Urine volume levels of albino rats given various 




Fig. 5: kidney weight to body weight ratio of albino rats given 
various treatments (values are mean ± SEM) *p=0.001 as 
compared to control group 
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Table 1: Urine chemistry of albino rats after atorvastatin treatments N=6 
Groups Treatments (Oral route) Urine Sodium meq/L Urine Potassium meq/L 
Group 1 Distilled Water 42.1± 1.53 75.15±2.02 
Group 1 Atorvastatin 5mg/kg p. 44.48±1.88 81.25±1.09 
Group 3 Atorvastatin 10mg/kg 40.22 ±1.33 78.2±1.14 
Group 4 Atorvastatin 20mg/kg 42.20±1.06 79.05±1.24 
 
Table 2: Renal anti oxidant enzymes levels of albino rats after atorvastatin treatments N=6 
Groups Treatments (oral) SODU/mg of 
protein  
Catalase nmols of H2O2 GSH nmols/ mg of 
protein  decomposed /mgin/mg of 
protein  
MDA nmols/mg of 
protein 
Group 1 Distilled Water  35.828±2.398 0.689±0.063 0.157±0.014 1.24 ±0.017 
Group 2 Atorvastatin 5mg/kg(p. o) 36.442±1.612 0.615±0.083 0.161±0.006 1.122±0.014 
Group 3 Atorvastatin 10mg/kg 34.003 ±1.061 0.771±0.045 0.130 ±0.007 1.506 ±0.169 
Group 4 Atorvastatin 20mg/kg+ 
Distilled Water 0.08 
ml/100g(i. p) 
33.561±1.134 0.687±0.083 0.127±0.009 1.335±0.113 
 
 
Fig. 6: Histopathology of kidney (40 x) of control rats showing 
normal tubules and glomerulus 
 
 
Fig. 7: Histopathology of kidney (40 x) of atorvastatin5mg/kg 
treated rats showing normal tubules and glomerular 
 
 
Fig. 8: Histopathology of kidney (40x) of atorvastatin10mg/kg 
treated rats showing normal tubules and glomerulei  
(mild comgestion) 
 
Fig. 9: Histopathology of kidney (40 X) of atorvastatin20mg/kg 
treated rats showing glomerlar atrophy and nephritis 
 
 
Fig. 10: Histopathology of kidney of atorvastatin20mg/kg 
treated rats showing dialated tubules 
 
DISCUSION 
Blood Urea Nitrogen, and Serum creatinine are indicators of kidney 
function. BUN and Serum creatinine levels of rats treated with 
atorvastatin 5mg/kg and 10mg/kg were not significantly different 
from that of control animals. It indicated that these doses of 
atorvastatin not induce any nephrotoxicity and did not cause 
impaired renal functions. But BUN and serum creatinine levels were 
significantly increased by high dose (20mg/kg) atorvastatin 
treatment compared to the control animals; it may be the result of 
atorvastatin induced renal damage at this dose. 
Creatinine clearance is also an index of renal functions and 
decreased clearance may be associated with decline in renal 
functions. In our study creatinine clearance did not changes 
significantly in rats treated with low doses of atorvastatin compared 
to the control animals. But atorvastatin at a dose of 20mg/kg caused 
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a significant fall in creatinine clearance as compared to the control 
and this fall in creatinine clearance is in agree with the report that a 
high dose statin was associated with decline in renal functions.  
Atorvastatin at a dose of 5mg/kg and 10mg/kg did not significantly 
decrease the urine volume compared to the control animals. But 
20mg/kg of atorvastatin significantly decreased the urine volume 
compared with control animals. Diminished urine volume may be 
the result of statin induced renal damage. Urine electrolytes (sodium 
and potassium) and serum potassium levels were not changed 
significantly in any of the statin treated groups compared with 
control animals. It may indicate that statin induced nephrotoxicity 
was not so prominent to affect the electrolytes balance in the urine 
and blood. The ratio of kidney weight to body weight of animals 
were significantly higher in atorvastatin 20mg/kg treated animals 
compared to the control animals. The increased kidney weight may 
be the result of nephrotoxicity associated with this dose.  
SOD, catalase, GSH and MDA are important indicators of antioxidant 
status. The level of SOD, catalase, GSH and MDA of rats treated with 
all the three doses (5mg/kg, 10mg/kg and 20mg/kg) of atorvastatin 
was comparable with that of the control animals; indicating that 
atorvastatin at these selected dose levels did not interfere with 
normal antioxidant status and not induce any oxidative stress 
sufficient to cause renal damage. 
In our previous study it was reported that atorvastatin at a dose of 
20mg/kg failed to provide a protection against vancomycin induced 
nephrotoxicity; even though this dose normalized the antioxidant 
status which was decreased due to vancomycin treatment. This may 
probably be due to the fact that atorvastatin itself had a nephrotoxic 
potential at a high dose and it was evidenced by renal 
histopathology of rats which received this dose alone without 
receiving vancomycin.  
Although the experimental evidence for statin induced direct renal 
damage was rare; a case was reported by Roal van Zyl-Smit et al 
where a patient developed direct tubular damage with high dose of 
atorvastatin and rosuvastatin statin therapy [17]. In this patient 
renal toxicity reflected by raised BUN, serum creatinine and 
diminished creatinine clearance and his renal biopsy showed acute 
as well as chronic tubulo interstitial nephritis. There was an increase 
in fibrous tissue with tubular atrophy and occasional inflammatory 
cells. Casts was seen in some parts of dilated tubules and contained 
detached renal tubular cells. The glomeruli were normal. D J 
Kornbrust et al reported that in rabbits treated with lovastatin 
showed renal tubular necrosis along with accumulation of serum 
urea nitrogen and creatinine [26]. 
The renal damage associated with statin may be due to the 
rhabdomyolysis caused by high dose statins. Rhabdomyolysis is an 
important but rare adverse effect of statins, which is characterized 
by severe muscle destruction with release of contents of damaged 
myocytes including myoglobin which cause damage to kidney and 
myoglobinuria. Occurrence of rhabdomyolysis with statin mostly 
been related to a combination with other agents that may interfere 
with statin metabolism [27]. Lewin J et al reported a case of a patient 
with rhabdomyolysis and accompanying acute renal failure 
secondary to a drug interaction between atorvastatin and diltiazem 
[28]. Maltz c et al reported a case of rhabdomyolysis in a cadaveric 
renal transplant patient receiving atorvastatin and cyclosporine 
concurrently [29]. Jimmy Jose et al reported a case of early-onset of 
rhabdomyolysis in a patient with nephrotic syndrome treated with 
atorvastatin [30]. Daniele Vallisa et al reported a case of fatal 
rhabdomyolysis associated with simvastatin treatment in a renal 
transplant patient who receive concurrent cyclosporine [31]. 
In our study also rhabdomyolysis may be the reason for 
impairedrenal function associated with high dose. But no visual 
change of muscle weakness such as difficulties in walking was 
observed at the treatment period. 
CONCLUSION 
The results of the study concluded that atrorvastatin at any of the 
tested dose levels not interfere with cellular anti-oxidant 
mechanism, oxidative stress is not a reason for statin induced renal 
damage. Further Studies with necessary biomarkers are needed to 
confirm the role of rhabdomyolysis in statin induced renal damage 
and studies are also needed to discriminate the dose of atorvastatin 
to cause rhabdolmyolysis when used alone or in combination with 
other agents interfering with statin metabolism. 
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